Hepatitis C

Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks just under the surface and warrant attention. Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless...

The Street may be too optimistic in its outlook for Gilead Sciences, Inc. (NASDAQ: GILD) — and this isn't a bullish indicator, according to Credit Suisse. The Analyst Credit Suisse's Alethia Young downgraded Gilead's stock rating from Outperform to Neutral with a price target...

Shares of Gilead Sciences, Inc. (NASDAQ: GILD) appear to be unaffected by reports that call into question the safety of hepatitis C drugs. The stock was trading higher by 0.47 percent at $72.25 ahead of Thursday's stock market open. According to Stat News, reports were filed with the U.S. Food and...

Barclays remains Overweight on Gilead Sciences, Inc. (NASDAQ: GILD) on valuation and franchise stability, despite reporting disappointing second-quarter results on the heels of hepatitis C drug Harvoni's continued sales declines. Harvoni, Sovaldi Sales for Harvoni plunged about 29 percent to $2.56...

The Wall Street Journal highlighted a U.S. Senate report on Gilead Sciences, Inc. (NASDAQ: GILD) saying that the pharmaceutical giant knew high prices for its Hepatitis C drug would put the medicine out of reach for many patients that needed the treatment. The company priced its Solvaldi...

Ex-"Baywatch" actress Pamela Anderson announced via her Instagram account that she has been cured of Hepatitis C. Anderson contracted the disease 16 years ago when she shared a tattoo needle with her then-husband Tommy Lee. Several of the largest biotech names are engaged in...

Johnson & Johnson (NYSE: JNJ) came out with better-than-expected earnings on Tuesday, despite the strong headwind it faced from the rising dollar. The company reported first-quarter EPS of $1.56, compared to $1.54 in the same quarter last year, while revenue dropped to $17.4 billion, from $18...

As the broad market charges to new all-time highs, not all stocks and sectors are participating. Two sectors that are going in the exact opposite directions of the market are issues in the healthcare sector and biotech sector. Free-Falling Now The charts of the iShares NASDAQ Biotechnology...

The hepatitis C industry has been on fire since Merck (NYSE: MRK) paid a 230 percent premium for pharmaceutical company Idenix (NASDAQ: IDIX). Benzinga spoke to Enanta (NASDAQ: ENTA) CEO Jay Luly about possibilities for his firm, which has one of the most expansive hepatitis C pipelines of all...

This month marks 33 years since the U.S. Centers for Disease Control and Prevention (CDC) reported on a rare lung infection affecting a group of gay men – one of the first known medical mentions of what later became known as the AIDS outbreak. The World Health Organization says that, over...

In this momentum-driven market, sector or company-specific news can have a significant impact on the price of individual issues. Wall Street analysts weighing in on the issue may also add to the momentum already in place. An example is Achillion Pharmaceuticals (NASDAQ: ACHN), where all of...